Macitentan Administration for Pulmonary Hypertension Due to β-thalassemia with Multiple Organ Failure
Open Access
- 1 June 2024
- journal article
- research article
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (11) , 1585-1590
Abstract
A 51-year-old Thai woman diagnosed with β-thalassemia underwent regular blood transfusion and iron-chelating therapy. However, after voluntarily discontinuing treatment, the patient developed progressive dyspnea and was diagnosed with pulmonary hypertension following right heart catheterization. Despite resuming blood transfusions, her condition did not improve. Because the patient had a history of multiple organ failure, curative treatment for β-thalassemia was not feasible, and macitentan was administered. Despite experiencing hypotension as an adverse event, her condition remained stable during macitentan treatment. Thus, macitentan may be well tolerated in patients with pulmonary hypertension caused by β-thalassemia with multiple organ dysfunction.Keywords
This publication has 20 references indexed in Scilit:
- Pulmonary Arterial Hypertension in a Patient with β‐Thalassemia Intermedia and Reversal with Infusion Epoprostenol Then Transition to Oral Calcium Channel Blocker Therapy: Review of LiteraturePulmonary Circulation, 2014
- Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of β-Thalassemia Patients Using Right Heart CatheterizationCirculation, 2014
- Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairmentThe Journal of Clinical Pharmacology, 2013
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertensionHaematologica, 2013
- Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertensionBlood, 2012
- Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studiesBritish Journal of Haematology, 2010
- Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokineticsBritish Journal of Clinical Pharmacology, 2006
- Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/β-thalassemia patientBlood, 2004
- The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafilBritish Journal of Clinical Pharmacology, 2002